Kymera Therapeutics (KYMR) EBT Margin (2019 - 2026)
Kymera Therapeutics' (KYMR) quarterly EBT Margin came in at 1439.7% in Q1 2026, down 55098.0% year-on-year from N/an in Q1 2025, and up 57.79% on a QoQ basis from 3411.01% in Q4 2025.
Kymera Therapeutics (KYMR) EBT Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of EBT Margin data on file, last reported at 1439.7% in Q1 2026.
- On a quarterly basis, EBT Margin fell 55098.0% year-over-year to 1439.7% in Q1 2026; TTM through Mar 2026 was 2241.92%, a 121204.0% decrease from a year earlier, with the FY2025 full-year figure at 1912.45%, down 85483.0% from the prior year.
- EBT Margin for Q1 2026 stood at 1439.7%, up from 3411.01% in the prior quarter.
- Over the last five years, EBT Margin for KYMR reached as high as 239.7% in Q4 2022 and fell as low as 12394.21% in Q3 2025.
- Historically, EBT Margin has averaged 2325.09% across 5 years, with a median of 1187.89% in 2023.
- On a YoY basis, EBT Margin climbed as much as 94891 bps in 2025 and fell as far as 647855 bps in 2025.
- Year by year, EBT Margin stood at 239.7% in 2022, then plunged by 58 bps to 379.42% in 2023, then tumbled by 188 bps to 1092.39% in 2024, then plunged by 212 bps to 3411.01% in 2025, then surged by 58 bps to 1439.7% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 1439.7% in Q1 2026, 3411.01% in Q4 2025, and 12394.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.11 Bn | - | -1,439.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,439.70% |
| Dec 31, 2025 | -3,411.01% |
| Sep 30, 2025 | -12,394.21% |
| Jun 30, 2025 | -1,906.61% |
| Mar 31, 2025 | -888.72% |
| Dec 31, 2024 | -1,092.39% |
| Sep 30, 2024 | -5,915.66% |
| Jun 30, 2024 | -420.89% |
| Mar 31, 2024 | -1,837.63% |
| Dec 31, 2023 | -379.42% |
| Sep 30, 2023 | -3,921.15% |
| Jun 30, 2023 | -1,010.91% |
| Mar 31, 2023 | -1,187.89% |
| Dec 31, 2022 | -239.70% |
| Sep 30, 2022 | -988.35% |
| Jun 30, 2022 | -741.27% |
| Mar 31, 2022 | -1,751.05% |
| Dec 31, 2021 | -223.00% |
| Sep 30, 2021 | -1,329.11% |
| Jun 30, 2021 | -1,197.33% |